Karin Ribi1, Weixiu Luo1, Jürg Bernhard1, Prudence A Francis1, Harold J Burstein1, Eva Ciruelos1, Meritxell Bellet1, Lorenzo Pavesi1, Ana Lluch1, Marilena Visini1, Vani Parmar1, Carlo Tondini1, Pierre Kerbrat1, Antonia Perelló1, Patrick Neven1, Roberto Torres1, Davide Lombardi1, Fabio Puglisi1, Per Karlsson1, Thomas Ruhstaller1, Marco Colleoni1, Alan S Coates1, Aron Goldhirsch1, Karen N Price1, Richard D Gelber1, Meredith M Regan1, Gini F Fleming1. 1. Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea
Abstract
PURPOSE: The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes. PATIENTS AND METHODS: The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor-positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, and annually during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6, 24, and 60 months with mixed models for repeated measures with and without chemotherapy and overall. RESULTS: Patients on tamoxifen plus OFS were more affected than patients on tamoxifen alone by hot flushes at 6 and 24 months, by loss of sexual interest and sleep disturbance at 6 months, and by vaginal dryness up to 60 months. Without prior chemotherapy, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamoxifen plus OFS. Symptom-specific treatment differences at 6 months were less pronounced in patients with prior chemotherapy. Changes in global QoL indicators from baseline were small and similar between treatments over the whole treatment period. CONCLUSION: Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control.
RCT Entities:
PURPOSE: The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes. PATIENTS AND METHODS: The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor-positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, and annually during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6, 24, and 60 months with mixed models for repeated measures with and without chemotherapy and overall. RESULTS:Patients on tamoxifen plus OFS were more affected than patients on tamoxifen alone by hot flushes at 6 and 24 months, by loss of sexual interest and sleep disturbance at 6 months, and by vaginal dryness up to 60 months. Without prior chemotherapy, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamoxifen plus OFS. Symptom-specific treatment differences at 6 months were less pronounced in patients with prior chemotherapy. Changes in global QoL indicators from baseline were small and similar between treatments over the whole treatment period. CONCLUSION: Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control.
Authors: A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2015-05-04 Impact factor: 32.976
Authors: Jürg Bernhard; Weixiu Luo; Karin Ribi; Marco Colleoni; Harold J Burstein; Carlo Tondini; Graziella Pinotti; Simon Spazzapan; Thomas Ruhstaller; Fabio Puglisi; Lorenzo Pavesi; Vani Parmar; Meredith M Regan; Olivia Pagani; Gini F Fleming; Prudence A Francis; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Barbara A Walley Journal: Lancet Oncol Date: 2015-06-16 Impact factor: 41.316
Authors: Amye J Tevaarwerk; Molin Wang; Fengmin Zhao; John H Fetting; David Cella; Lynne I Wagner; Silvana Martino; James N Ingle; Joseph A Sparano; Lawrence J Solin; William C Wood; Nicholas J Robert Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Elizabeth Maunsell; Paul E Goss; Rowan T Chlebowski; James N Ingle; José E Alés-Martínez; Gloria E Sarto; Carol J Fabian; Pascal Pujol; Amparao Ruiz; Andrew L Cooke; Susan Hendrix; Debra W Thayer; Kendrith M Rowland; Pierre Dubé; Silvana Spadafora; Sandhya Pruthi; Lavina Lickley; Susan L Ellard; Angela M Cheung; Jean Wactawski-Wende; Karen A Gelmon; Dianne Johnston; Andrea Hiltz; Michael Brundage; Joseph L Pater; Dongsheng Tu; Harriet Richardson Journal: J Clin Oncol Date: 2014-04-07 Impact factor: 44.544
Authors: Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber Journal: N Engl J Med Date: 2014-12-11 Impact factor: 91.245
Authors: Meredith M Regan; Olivia Pagani; Gini F Fleming; Barbara A Walley; Karen N Price; Manuela Rabaglio; Rudolf Maibach; Barbara Ruepp; Alan S Coates; Aron Goldhirsch; Marco Colleoni; Richard D Gelber; Prudence A Francis Journal: Breast Date: 2013-10-02 Impact factor: 4.380
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Karin Ribi; Alan Coates; Lynette Blacher; Meredith M Regan; Richard D Gelber; Jürg Bernhard Journal: Qual Life Res Date: 2017-09-05 Impact factor: 4.147
Authors: G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann; F André; J Baselga; J Bergh; H Bonnefoi; S Y Brucker; F Cardoso; L Carey; E Ciruelos; J Cuzick; C Denkert; A Di Leo; B Ejlertsen; P Francis; V Galimberti; J Garber; B Gulluoglu; P Goodwin; N Harbeck; D F Hayes; C-S Huang; J Huober; K Hussein; J Jassem; Z Jiang; P Karlsson; M Morrow; R Orecchia; K C Osborne; O Pagani; A H Partridge; K Pritchard; J Ro; E J T Rutgers; F Sedlmayer; V Semiglazov; Z Shao; I Smith; M Toi; A Tutt; G Viale; T Watanabe; T J Whelan; B Xu Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Poornima Saha; Meredith M Regan; Olivia Pagani; Prudence A Francis; Barbara A Walley; Karin Ribi; Jürg Bernhard; Weixiu Luo; Henry L Gómez; Harold J Burstein; Vani Parmar; Roberto Torres; Josephine Stewart; Meritxell Bellet; Antonia Perelló; Faysal Dane; Antonio Moreira; Daniel Vorobiof; Michelle Nottage; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Marco Colleoni; Gini F Fleming Journal: J Clin Oncol Date: 2017-06-27 Impact factor: 44.544
Authors: Prudence A Francis; Olivia Pagani; Gini F Fleming; Barbara A Walley; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Eva Ciruelos; Harold J Burstein; Hervé R Bonnefoi; Meritxell Bellet; Silvana Martino; Charles E Geyer; Matthew P Goetz; Vered Stearns; Graziella Pinotti; Fabio Puglisi; Simon Spazzapan; Miguel A Climent; Lorenzo Pavesi; Thomas Ruhstaller; Nancy E Davidson; Robert Coleman; Marc Debled; Stefan Buchholz; James N Ingle; Eric P Winer; Rudolf Maibach; Manuela Rabaglio-Poretti; Barbara Ruepp; Angelo Di Leo; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Meredith M Regan Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245
Authors: Meredith M Regan; Prudence A Francis; Olivia Pagani; Gini F Fleming; Barbara A Walley; Giuseppe Viale; Marco Colleoni; István Láng; Henry L Gómez; Carlo Tondini; Graziella Pinotti; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544
Authors: Matteo Lambertini; Halle C F Moore; Robert C F Leonard; Sibylle Loibl; Pamela Munster; Marco Bruzzone; Luca Boni; Joseph M Unger; Richard A Anderson; Keyur Mehta; Susan Minton; Francesca Poggio; Kathy S Albain; Douglas J A Adamson; Bernd Gerber; Amy Cripps; Gianfilippo Bertelli; Sabine Seiler; Marcello Ceppi; Ann H Partridge; Lucia Del Mastro Journal: J Clin Oncol Date: 2018-05-02 Impact factor: 44.544